Direct Evidence of the Importance of Stromal Urokinase Plasminogen Activator (uPA) in the Growth of an Experimental Human Breast Cancer Using a Combined uPA Gene-Disrupted and Immunodeficient Xenograft Model

Thomas Leth Frandsen, Claus Holst-Hansen, Boye Schnack Nielsen, Ib Jarle Christensen, Jens R. Nyengaard, Peter Carmeliet, and Nils Brünnér

ABSTRACT

Several studies have indicated an interaction between tumor cells and infiltrating stromal cells regarding the urokinase plasminogen activation (uPA) system. By developing combined uPA gene-disrupted and immunodeficient mice, we have studied the role of stromal uPA for the growth of the MDA-MB-435 BAG human tumor xenograft. Subcutaneous tumor growth and lung metastasis were compared between wild-type immunodeficient mice and mice with the combined deficiencies. Tumor growth was evaluated by volume measurements and plasma β-galactosidase activity and metastasis was evaluated by counting lung surface metastases. Although no differences appeared in primary tumor take between the two groups of mice, a significant difference was observed in primary tumor growth, with tumors in uPA−/− mice growing significantly more slowly. In addition, a nonsignificant trend toward fewer lung metastases in uPA−/− mice was observed. The present data points to a critical role of stromal-derived uPA in the primary tumor growth of MDA-MB-435 BAG xenografts, whereas only a trend toward fewer lung metastases in uPA gene-disrupted mice was found.

INTRODUCTION

Proteinases such as matrix metalloproteinases, serine proteinases, and cystein proteinases have been suggested to play a critical role in cancer progression, i.e., tumor growth, invasion, and dissemination. In particular, the urokinase plasminogen activation system, constituting uPA, its specific receptor, uPAR, and its inhibitors, PAI-1 and PAI-2 have in experimental in vivo tumor models been shown to be involved in these processes. uPA is secreted as an inactive single-chain proenzyme (pro-uPA), which is converted by limited proteolysis into the enzymatically active two-chain uPA, which in turn cleaves plasminogen, resulting in the formation of the broad spectrum proteolytic enzyme plasmin. Both pro-uPA and uPA bind with high affinity to a specific cell surface receptor, uPAR. Concomitant cell surface binding of uPA and plasminogen fociates and enhances plasmin formation to the close vicinity of the cell surface. Formation of uPA-PAI-1 complexes on the cell surface leads to internalization of the uPAR-uPA-PAI-1 complexes.

In situ hybridization and immunohistochemistry studies of human breast cancer tissue have shown that uPA mRNA and protein is mainly expressed by myofibroblasts surrounding nests of cancer cells (1), whereas uPAR is mainly expressed by infiltrating macrophages (2), suggesting that the stromal-cell components of the tumor tissue are actively involved in the expression of proteolytic activity. Whether these stromal cells represent a particular subpopulation of stromal cells that are recruited into the tumor tissue, or whether they are preexisting but induced by the tumor cells to produce proteinases, has not yet been clarified. We have shown previously that in human breast tumors grown in immunodeficient mice, murine uPA is expressed by the mouse stromal cells with a pattern similar to that described in human breast cancer (3).

Experimental in vitro and in vivo studies have shown that inhibition of uPA activity or uPA-binding to uPAR results in tumor growth inhibition and reduced or abolished formation of metastasis (4–8). uPA is most probably facilitating cancer invasion by stimulating extracellular matrix degradation, but the exact role of uPA in regulating tumor growth is not fully understood. uPA may also be involved in activation of latent growth factors, e.g., latent transforming growth factor β (9), and release of growth factors that are bound to the extracellular matrix, e.g., basic fibroblast growth factor (10), and thereby regulate the growth of tumors by increasing the liberation and availability of these growth factors. In addition, uPA has been directly associated with cell proliferation, migration, and chemotaxis (11–16), all events that could have a significant impact on tumor cell dissemination.

Mice made genetically deficient for uPA show only minor phenotypic changes, such as occasional fibrin deposition in the intestines and in the sinuses of the liver (17). uPA-deficient mice have, in addition, been shown to have impaired neoONTA formation after electric or mechanical injury of arteries, possibly attributable to an impaired cellular migration of smooth muscle cells (18–20), and a recent study showed that during the first 3 days of life, the epidermis from uPA gene-deficient mice have a significantly lower proliferative rate than the epidermis from wild-type mice, suggesting a role of uPA in epidermal cell proliferation (15). In accordance, wound-healing experiments have shown delayed healing in uPA gene-deficient mice (21). In another study, chemical induction of melanocytic neoplasms in mice revealed that wild-type and uPA gene-deficient mice developed blue nevi with the same frequency, whereas only wild-type mice had the ability to develop melanomas, suggesting a critical role of uPA in the final progression toward the fully developed malignant phenotype (22).

In the present study, we have established combined uPA gene-disrupted and immunodeficient mice. By transplanting a human cell line expressing only small amounts of human uPA into these mice and their wild-type littermates, we have tested the hypothesis that stromal uPA plays an important role in the growth and dissemination of this xenograft tumor model. The results support a direct role of stromal uPA in the growth regulation of the MDA-MB-435 BAG xenograft, whereas only a trend toward fewer metastasis in uPA gene-disrupted mice was found.

MATERIALS AND METHODS

Animals. Mice were kept in micro-isolation cages and fed a regular chow. The generation of uPA−/− mice has been described previously (17). The uPA
gene-targeted mice of a mixed C57Bl/6J/129 background were backcrossed 5 generations into the META/Bom strain of BALB/c background (Bomholtgaard, Ry, Denmark). Littermate offspring were made by mating a uPA+/−/METABom nu/nu male with a uPA−/−/female of the META/Bom nu/+ genotype. In all experiments involving wild-type mice as controls, these were littermates to the uPA-deficient mice. All mice used for experiments were between 8–12 weeks old at the start of the experiment. All experimental evaluations were performed by an investigator unaware of animal genotype.

For the initial characterization of uPA mRNA expression and protein production, the three included human breast cancer cell lines (see below), were grown in female META/Bom nu/nu mice. All animal experiments were performed according to the guidelines published by the Danish Animal Care Committee (permission no. 1998/589-146).

Genotyping was performed by standard procedure PCR analysis of tail DNA specimens. Genotyping of the animals was performed before and after experiments. The following primers were used: (a) Neo, 5′ ATT GTG AAA CAA GAT GGA TGG CAC G 3′; 5′ TTC GTC CAG ATC ATG ATC GAC 3′; and (b) uPA, 5′ CTG GAA TGG GCC TGC TGT CCT TCA 3′; and TGT CAC GAG CTC CCC TGA TCA 3′.

**Cell Lines.** Human breast cancer cell lines MDA-MB-435 BAG, MDA-MB-231 BAG, and MCF-7 BAG, which have been transduced with a cDNA library of human mRNA, were cultured in Eagle’s MEM supplemented with 10% FCS, 10% v/v inactivated normal mouse serum, and 1% antibiotics.

**In Situ Hybridization.** The probe to murine uPA, designated pMUPA07, is a 608-1642-bp cDNA fragment in pGEM5z, whereas the probe to human uPA, designated pHUPA13, is a 791-1303-bp cDNA fragment in pBlueScript KS(+). Plasmids were linearized using the following restriction endonucleases: (a) pMUPA07, EcoRI or PstI; (b) pHUPA13, HindIII. The probes obtained from these plasmids are specific for murine or human uPA mRNAs and do not cross-react (3). Generation of 32P-UTP-labeled antisense and sense probes was performed by in vitro transcription of the plasmids using the relevant RNA polymerases (3). All probe preparations, including both sense and antisense probes, were adjusted to 1×106 cpm/μg.

**Lung Metastasis.** Lung metastases were stained and counted essentially as described previously (23). Briefly, anesthetized animals were PBS-perfused, after which the lungs were dissected from the animals and placed in a mixture of 2% (v/v) parafomaldehyde and 0.2% (v/v) glutaraldehyde in PBS for 3–4 h at 4°C. After fixation, the tissue blocks were rinsed three times with PBS and then incubated for 24 h at 4°C in 1 mg X-gal/ml; 35 mmol/l potassium ferricyanide; 35 mmol/l potassium ferrocyanide; 2 mmol/l MgCl2; 0.02% (v/v) NP40; and 0.01% (w/v) sodium deoxycholate in PBS. The lungs were then rinsed, first with 3% (v/v) dimethyl sulfate in PBS and then with PBS only. Until evaluation of surface metastases, the lungs were stored at 4°C in 0.02% sodium azide in PBS. Metastases were evaluated by counting surface metastases through an inverted dissecting microscope.

**β-Gal Measurement in Plasma.** Blood was obtained from each mouse, and citrate plasma was separated. Plasma β-gal activity was measured by an immunocapture assay as described previously (30). Briefly, white microwell plates (Berthold, Bad Wildbad, Germany) were coated for 16 h at 4°C with 200 μl/well of the murine monoclonal antibody to Escherichia coli β-gal clone 5B88 (2.5 μg/ml; Life Technologies, Inc., Gaithersburg, MD) in 0.1 M carbonate buffer (pH 9.5). Before use, the assay wells were rinsed once with 200 μl/well of SuperBlock solution (Pierce Chemicals, Rockford, IL) diluted 1:1 with PBS, and then by three washes with PBS containing 1 mg/ml Tween 20. Wells were then incubated for 1 h at 37°C with 200 μl/well in triplicate of 1:20 diluted plasma samples. After β-gal binding, the wells were washed three times with PBS containing 1 mg/ml Tween 20 and then treated for 45 min at 37°C with 200 μl/well of Galacto-Light Reaction Buffer Diluent with Galacto-Plus chemiluminescent substrate (Tropix, Bedford, MA). After the enzymatic cleavage of the substrate, chemiluminescent light emission was triggered by adding automatically 100 μl/well of the alkaline phosphatase enhancer (Accelerator II; Tropix) using the pump incorporated in the luminometer (Berthold LB 960 P-2 MicroLumat). Chemiluminescence intensity (relative light units) was measured over a 5-s interval with a delay time of 2 s. The results are presented as the mean ± SE.

**CD34 Immunochemistry.** Five-μm paraffin sections of the tumors were deparaffinized in xylene and hydrated through ethanol/water dilutions. Proteolytic digestion was performed with 0.025% trypsin (Sigma T8128) in 50 mM Tris (pH 7.6) containing 0.1% CaCl2 for 7 min at 37°C. Sections were blocked for endogenous peroxidase activity by 1% hydrogen peroxide for 15 min. Then, sections were washed in TBS (50 mM Tris, 150 mM NaCl (pH 7.6)) containing 0.5% Triton X-100. Slides were mounted into Shandon sequenza slide racks with immunostaining cover plates (Shandon Inc. Pittsburgh, PA, USA), for additional incubations. The sections were incubated overnight at 4°C with rat antobody CD34 clone MEC 14.7, HyCult Biotechnology, Uden, Netherlands) at 1:30 (3 μg/ml). The rat antibody was detected with affinity purified biotinylated rabbit antirabbit antibodies (E468, Dako, Glostrup, Denmark) followed by streptavidin horseradish peroxidase complexes (Dako, Glostrup, Denmark). Each antibody incubation was followed by washes with 6 ml of Triton X-100. Sections were developed with NovaRED substrate as specified by the manufacturer (Vector Laboratories, Burlingame, CA) for 10 min. Finally, sections were counterstained in diluted Mayers Hematoxylin for 30 s, dehydrated in ethanol, and mounted.

**Quantitation of Angiogenesis.** The computer-assisted stereology setup consisted of a Leica Dialux 22 microscope equipped with a CCD Camera (JAI 2040) and a motorized X-Y stage directed by a multicontroller unit (Olympus, Alberslund, Denmark). The computer (IBM, PC 300 GL) had a 24-bit frame-
The vascular length density was estimated with an unbiased counting frame as described by Gundersen et al. (31), with the assumption that the vessels were isotropic in the tumor. Counting was performed on CD34 immunohistochemically stained sections (two from each tumor), which were slightly counterstained with hematoxylin. The overall magnification used on the computer monitor was ×318. The vascular length density \[L_v(vasc/tumor)\] estimates were obtained by counting vascular profiles \[Q_v(vasc)\] within the counting frame. The upper right corner was used to estimate the tumor tissue by point-counting \[2P(tumor)\]. The area associated to this test point was denoted \((a/p)\). Only vital tumor areas and vascular profiles located within living tumor areas were counted. The vascular length density was estimated as:

\[L_v(vasc/tumor) = \frac{Q_v(vasc)}{2 \cdot (2 \cdot \Sigma P(tumor))}\]

The average radius of the living tumor around a “typical” capillary, which may be interpreted as the average maximal diffusion distance from capillary to tumor, \(\bar{r}\) (tumor/vasc), was obtained by:

\[\bar{r}(tumor/vasc) = (\pi \cdot L_v(vasc/tumor))^{-1/2}\]

The total length of vessels in vital tumor tissue was obtained by

\[L(vasc) = L_v(vasc/tumor) \cdot V(tumor)\]

Statistical Methods. For the comparison of primary tumor growth curves of the two groups, repeated measures of ANOVA were used. The statistical significance of differences in plasma β-gal activity, vascular length density, maximal diffusion distance, and total length of vessels were analyzed by Student’s t test. The number of metastases formed in the two groups was compared by Fischer’s exact test and the nonparametric Mann-Whitney test. In all statistical analyses, \(P < 0.05\) were considered statistically significant.

RESULTS

Expression of Human and Murine uPA mRNA and Human uPA Protein in Xenografted Tumors. To select a human breast cancer xenograft with low endogenous human-uPA expression, Northern blot analysis using a human-specific cDNA uPA probe (3) was performed on total RNA purified from primary tumor xenografts. MDA-MB-231 BAG cells expressed measurable levels of human uPA mRNA, whereas a total lack of signal was found in MDA-MB-435 BAG and MCF-7 BAG tumors (Fig. 1). Extracts from MDA-MB-231 BAG and MDA-MB-435 BAG tumors were investigated in a human-specific uPA ELISA, and in accordance with the Northern blot analysis, the ELISA measurement showed that whereas MDA-MB-231 BAG tumors express high amounts of human uPA (84 ng/mg protein ± SD), MDA-MB-435 BAG cells contained 400-fold less uPA/mg protein (0.22 ng/mg protein ± SD). By applying the ELISA to a standard curve of murine uPA, it was confirmed that this assay does not detect mouse pro-uPA (not shown). Thus, the uPA protein measured is exclusively produced by the human cancer cells.

Because the MDA-MB-435 BAG xenografts express a low level of human uPA mRNA and protein, and because MDA-MB-435 BAG xenografts, different from MCF-7 xenografts, are known to grow locally invasive and to form lung metastases (23), this xenograft was selected for additional experimentation.

In Situ Hybridization of Human and Murine uPA. In situ hybridization of MDA-MB-435 BAG xenografts for human uPA using a species-specific RNA probe (3), showed a weak but homogenous

signal over the tumor cells, with no signal observed in the host stromal tissue (data not shown). No specific signal was obtained by the corresponding sense probe (data not shown). In contrast, when using the mouse-specific probe, distinct regions of murine uPA expression were apparent within the stromal cells of the tumors. Expression was predominantly seen at the stromal regions near the tumor periphery, usually in the areas of invasion (Fig. 2, A and C). Murine uPA mRNA was also strongly expressed in regions bordering the necrotic areas (Fig. 2, B and D). At higher magnification, murine uPA was found to be expressed by stromal cells near the tumor-stroma border, including some endothelial-like cells. Although some endothelial cells (or cells in the vicinity of endothelial cells) did appear to express murine uPA mRNA, the signal was generally not associated with vascular-appearing structures, suggesting nonendothelial stromal cells as the major expressors of murine uPA. No murine uPA mRNA signal was detected in tumors obtained from uPA−/− mice or when using the sense probe on tumors from wild-type mice (data not shown).

Formation of MDA-MB-435 BAG Tumors in uPA+/− Immuno- nedeficient Mice and in Combined uPA Gene-Disrupted and Immuno- nedeficient Mice (uPA−/−). Three separate experiments were performed, including a total of 34 uPA−/− and 36 uPA+/− immunodeficient mice, each of which had bilateral tumor cell inoculation. In all three experiments, the mice were sacrificed about day 50, when tumors in the uPA−/− mice had reached a mean volume of approximately 2000 mm³.

In the uPA+/− mice, 34 of 34 animals (100%) developed tumors in the experimental period. MDA-MB-435 BAG cells formed tumors in uPA−/− mice with the same frequency as in uPA+/− mice, suggesting that host (murine) uPA is not essential for MDA-MB-435 BAG tumor formation. No differences in length of lag phase (time to palpable tumors) was observed between tumors growing in the two mouse genotypes.

MDA-MB-435 BAG tumors in uPA+/− mice grew rapidly and
reached a mean size of 2000 mm$^3$ 50 days after cell inoculation (Fig. 3A). In contrast, tumors grown in uPA$^{-/-}$ mice had a significantly slower growth rate reaching a mean size of 1200 mm$^3$ 50 days after cell inoculation ($P = 0.007$). The growth curves shown in Fig. 3A included 20 uPA$^{+/+}$ and 19 uPA$^{-/-}$ mice, and presents one experiment (experiment 3) representative of the three separate experiments performed.

We have recently reported a direct correlation between tumor size and plasma β-gal activity in mice carrying MDA-MB-435 BAG tumors (32). Thus, to confirm in a more objective manner the differences in the size of tumors growing in uPA$^{+/+}$ versus uPA$^{-/-}$ mice, plasma β-gal content of tumor-bearing mice was measured. Data from experiments 2 and 3 were combined. Whereas uPA$^{+/+}$ mice had a mean plasma β-gal activity of 35,000 (range, 276–178,000; $n = 24$) the mean β-gal activity measured in uPA$^{-/-}$ tumor bearing mice was significantly lower (9,230, Range 327–38,900; $n = 29$; $P = 0.006$), thus confirming the observed differences in tumor volume (Fig. 3B).

Local Invasion and Metastasis Formation of MDA-MB-435 BAG Xenografts. Histological inspection of the tumors grown in uPA$^{+/+}$ or uPA$^{-/-}$ mice showed that the tumors grew locally invasive, infiltrating the peritoneal wall of the animals in both groups. Fig. 2, E and F, show a representative area with invasion of MDA-MB-435 BAG cells into the peritoneal wall of a uPA$^{-/-}$ mouse.

Lungs from tumor-bearing animals in experiment 3 were removed at autopsy (day 52) and processed for X-gal staining. Eighteen of 20 lungs from wild-type mice were evaluable. Fourteen of 18 (78%) of uPA$^{+/+}$ mice had stereomicroscopically visible metastases (blue dots) on the surface of the lungs. In contrast, only 10 out 19 uPA$^{-/-}$ mice (53%) showed surface lung metastases. Fishers exact test showed that uPA$^{-/-}$ mice had a trend toward a reduced number of animals with lung metastases ($P = 0.2$). By counting the number of surface metastasis (blue dots) on individual lungs, the mean number of metastases was 3.8 in wild-type mice and 1.9 in uPA$^{+/+}$ mice. This difference is significant ($P = 0.001$).

Fig. 2. Murine-uPA mRNA expression as determined by in situ hybridization on MDA-MB-435 BAG xenografted tumors grown in wild-type mice (A, B, C, and D). A and C demonstrate an area of invasion into musculus panniculus of the host. B and D show an area of necrosis and non-necrotic tumor tissue. Arrows show areas of murine uPA mRNA expression. E and F are HE stainings of an area in a MDA-MB-435 BAG xenografted tumor in a uPA$^{-/-}$ mouse. The cancer cells invade the abdominal muscle of the host. T, non-necrotic tumor tissue; M, peritoneal muscle tissue. G and H show CD34 immunostaining of the MDA-MB-435 BAG xenografted tumor grown in a wild-type (G) or in a uPA deficient mouse (H). Arrows, CD34-positive vessels. A, B, E, F, G, and H are bright-field and C and D are dark-field micrographs. Scale bar: 100 µm (A, B, C, D, and E); 50 µm (F, G, and H).
tases in uPA\(^{+/+}\) mice was 12.7 (range, 0–36) whereas the mean number of surface lung metastases in uPA\(^{-/-}\) was 4.7 (range, 0–80). By applying the Mann-Whitney nonparametric test, a trend appeared toward fewer lung surface metastases in uPA\(^{-/-}\) mice (\(P = 0.15\)).

Thus, the difference between the groups regarding lung metastases did not reach statistical significance, but a tendency toward fewer metastases in the uPA\(^{-/-}\) mice was evident.

**CD34 Immunostaining of MDA-MB-435 BAG Tumors.** Microscopic inspection of CD34-stained MDA-MB-435 BAG tumors from both uPA\(^{+/+}\) and uPA\(^{-/-}\) mice revealed positively stained vessels and capillaries throughout the tumor tissue (Fig. 2, G and H) and in the connective tissue surrounding the tumors.

No obvious differences appeared between the two groups, including no apparent differences in size or morphology.

**Quantitation of Tumor Angiogenesis.** In experiment 2, stereological evaluation of the number of CD34-immunostained capillaries (vascular profiles) showed a nonsignificant difference (\(P = 0.15\)) in vascular length density between uPA\(^{-/-}\) mice (\(n = 11; 19 \pm 4\) profiles/mm\(^2\)) and uPA\(^{+/+}\) mice (\(n = 8; one mouse was lost before termination of the experiment; 22 \pm 4\) profiles/mm\(^2\)). In addition to vascular length density, we examined at average maximal diffusion distance from capillary to tumor (0.13 mm ± 0.01 (SE in uPA\(^{-/-}\) mice and 0.12 mm ± 0.004 (SE in uPA\(^{+/+}\) mice) as well as total length of vessels in vital tumor tissue (8.5 m ± 1.7 (SE in uPA\(^{-/-}\) mice and 14.0 m ± 4.6 (SE in uPA\(^{+/+}\) mice). In both cases we found the differences to be nonsignificant (\(P = 0.16\) and \(P = 0.23\), respectively), but with a trend toward reduced angiogenesis in tumors grown in the uPA gene-deficient mice. Thus, for all 3 types of measurements for tumor angiogenesis, we found a nonsignificant trend toward lower tumor angiogenesis in the uPA\(^{-/-}\) mice as compared with uPA\(^{+/+}\) mice.

**DISCUSSION**

In the present study we used combined uPA gene-disrupted and immunodeficient mice as well as species-specific quantitation systems, which allowed us to investigate the importance of host stromal/cancer cell interactions with regard to uPA. The results obtained provide direct evidence of a nonsignificant trend of lower stromal cell-produced uPA.

For the mRNA expression studies, the applied human- and mouse-specific uPA probes were clearly species-specific, and by including both murine and human uPA standard curves in the ELISA, we unequivocally demonstrated that this uPA ELISA does react with human, but not with murine, uPA. By the use of littermate animals as controls, we have attempted to minimize other host factors than uPA, influencing tumor growth and dissemination. Genotypes of the animals included in the experiments were in addition to PCR analyses, confirmed by subsequent murine uPA in situ hybridizations of the tumors.

We have described previously that mouse uPA is expressed in the human MDA-MB-231 breast cancer when grown in nude mice (3). Although using another human breast cancer cell line in the present study, the data confirm that the murine compartment of the human breast cancer xenografts express uPA. The murine uPA mRNA expression in MDA-MB-435 BAG tumors was confined to fibroblast-like cells, however, not all stromal cells with fibroblast-like appearance expressed murine uPA. Thus, the expression pattern of murine uPA in the xenografted human tumors resembles that described for human breast cancer (1).

The binding of uPA to its receptor strongly enhances cell-surface plasminogen activation (33). However, uPA binding to uPAR shows strict species specificity, e.g., murine uPA does not bind human uPAR and vice versa (34). Thus, to fully exert its proteolytic potential, murine uPA must bind murine uPAR. In our previous study of MDA-MB-231 xenografts (3), murine uPA and uPAR were shown to be expressed by cells that were either the same or located very close to each other. Although we did not include analysis of murine uPAR in the present study, we assume that murine uPAR is also expressed in MDA-MB-435 BAG xenografts. Thus, coexpression of murine uPA and uPAR in the same or adjacent cells in the xenografted tumors makes it likely that the murine uPA system is involved in plasmin generation in the tumor tissue. The exact mechanisms regulating stromal cell uPA expression in tumors is unknown. In vitro studies have shown that a number of cytokines regulate uPA expression (35). In the xenografted tumors, the human cancer cells may be the source of cytokines, which, by a paracrine mechanism, induces uPA (and uPAR) expression in the surrounding stromal cells.

There is ample experimental evidence that uPA has importance for tumor cell growth, e.g., it has been shown by different groups that uPA has a direct stimulatory effect on tumor cell proliferation in vitro (11, 12). Inhibition of uPA activity (6, 7) or inhibition of uPA-uPAR interaction (36, 37), results in impaired growth of experimental tumors. However, of particular interest is that in a recent experimental in vivo study (36) using the MDA-MB-231 human xenograft implanted into immunodeficient mice, both human and murine uPA-uPAR antagonists showed significant inhibition of primary tumor growth, suggesting that both tumor- (human) and stromal- (murine) cell uPAR dependent plasminogen activation can modulate tumor growth in vivo.

Our experimental data are in agreement with the study of Tressler et al. (36). By genetic disruption of the uPA gene, we have shown that tumors grown in the gene-deleted animals have a significantly slower growth rate than tumors grown in littermate control animals. One explanation to the observed decreased growth rate of tumors in uPA\(^{-/-}\) mice is that the local activation/release of growth factors is decreased attributable to decreased proteolytic activity in the tumor tissue (9, 10). Another explanation relates to the putative role of proteinases in the angiogenic process. Although the bioavailability of growth factors such as basic fibroblast growth factor, which is a highly efficient stimulator of angiogenesis, may be reduced in the tumor tissue of the uPA\(^{-/-}\) mice, proteinases have also been ascribed a direct role in the migration of endothelial cells (review by Pepper et al. in Ref. 38). Endothelial cells express both uPA and uPAR (38, 39), and the interaction between these two molecules may govern endothelial cell migration in the extracellular matrix. In support of this notion is the demonstration of decreased angiogenesis in murine tumors exposed to a murine uPA-uPAR-inhibitor (37). In our study we found a nonsignificant trend toward a lower angiogenesis as measured by vascular density, total vascular length, as well as the maximal diffusion distance, in tumors in the uPA\(^{-/-}\) mice.

Dissemination of cancer cells with subsequent formation of secondary tumors (metastasis), require protease activity and the ability to migrate and attach of not only the cancer cells but also of cells of the supporting stroma. A number of experimental tumor studies have shown that inhibition of uPA activity (4, 5) or uPA-uPAR interaction (40) results in a reduced number of metastatic foci. In our model, a difference although not significant was seen between uPA\(^{+/+}\) and uPA\(^{-/-}\) mice with regard to the number of lung surface metastases formed from the primary tumors, suggesting that stromal uPA is also involved in the mechanisms of metastasis formation. However, because of the significant effect of uPA-deficiency on the growth of the primary tumors, it cannot be excluded that the effect seen on the number of lung surface metastases reflects the effect on growth, i.e., some of the metastases in the uPA\(^{-/-}\) mice are under the detection limit of our evaluation system. In support of this notion is that tumors

536
showed an invasive growth pattern in both wild-type and uPA−/− mice.

In conclusion, the experimental data obtained points to a direct role of stromal-derived uPA for the growth of the human MDA-MB-435 BAG breast cancer xenograft.

REFERENCES


FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

2002 April 6–10, San Francisco, CA
2003 April 5–9, Toronto, Ontario, Canada
2004 March 27–31, Orlando, FL

AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR’s website (http://www.aacr.org).

MOLECULAR IMAGING IN CANCER: LINKING BIOLOGY, FUNCTION, AND CLINICAL APPLICATIONS IN VIVO
January 23–27, 2002
Disney’s Contemporary Resort, Lake Buena Vista, FL
Chairpersons
David Piwnica-Worms, St. Louis, MO
Thomas J. Meade, Pasadena, CA
Patricia M. Price, Manchester, England

APOTOPSIS AND CANCER: BASIC MECHANISMS AND THERAPEUTIC OPPORTUNITIES IN THE POST-GENOMIC ERA
February 13–17, 2002
Hilton Waikoloa Resort, Waikoloa, Hawaii
Chairpersons
John C. Reed, La Jolla, CA
Scott W. Lowe, Cold Spring Harbor, NY

THE MOLECULAR GENETICS OF COLON CANCER
March 7–10, 2002
Loew’s Philadelphia Hotel, Philadelphia, PA
Chairpersons
Anil K. Rustgi, Philadelphia, PA
Raju Kucherlapati, Bronx, NY

ONCOGENOMICS 2002: DISSECTING CANCER THROUGH GENOME RESEARCH
May 1–5, 2002
Burlington Hotel, Dublin, Ireland
Chairpersons
Jeffrey M. Trent, Bethesda, MD
Bette Phimister, New York, NY

Announcements

(Requests for announcements must be received at least three months before publication.)

CALENDAR OF EVENTS

Fourth International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Cell Biology and Clinical Research, January 10–13, 2002, Adam’s Mark Hotel, Dallas, TX. Contact: Kim Pearson, The CBCE, 8445 Freeport Parkway, Suite 680, Irving, TX 75063. Phone: 972.929.1900 (x104); Fax: 972.929.1901; E-mail: symposia@theCBCE.com.

13th Annual Colorectal Disease Symposium: An International Exchange of Medical and Surgical Concepts, February 14–16, 2002, Marriot’s Harbor Beach Resort and Spa, Fort Lauderdale, FL. 25.5 Category I CME credit hours. Contact: Cleveland Clinic Florida, Department of Continuing Education, 2950 Cleveland Clinic Boulevard, Weston, FL 33331. Phone: 954.659.5490; Fax: 954.659.5491; E-mail: cme@ccf.org; Website: www.cmeccf.com.

7th Annual NCCN Conference: Practice Guidelines and Outcomes Data in Oncology, February 28–March 3, 2002, Westin Diplomat Resort and Spa, Hollywood, FL. Contact: Tricia Wilson, National Comprehensive Cancer Network, 50 Huntington Pk, Suite 200, Rockledge, PA 19046. Phone: 215.728.2577; Fax: 215.728.3877; E-mail: information@nccn.org; Website: www.nccn.org.

International Symposium on Antimitogenesis and Anticarcinogenesis, April 26, 2002, New York Medical College, Valhalla, New York. Contact: Kathy Woodley, Basic Science Building, New York Medical College, Valhalla, NY 10595. Phone: 914.594.3084; Fax: 914.594.4163; E-mail: Kathy_Woodley@nymc.edu.

Molecular, Biologic, and Genetic Mechanisms Underlying Molecular Cancer: Implication of Early Detection, Screening, and Prevention, May 6–7, 2002, Magee Women’s Hospital, Main Auditorium, Pittsburgh, PA. Contact: Lori Burleigh, Women’s Health Program, University of Pittsburgh, PA 15260. Phone: 412-624-3045; Fax: 412-624-1056.

15th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology: Recent Advances in Steroid Biochemistry and Molecular Biology, May 17–20, 2002, Munich, Germany. Contact: Prof. J. R. Pasqualini, Institut de Puériculture, 26 Boulevard Brune, 75014 Paris, France. Phone: 33-1.45.42.61.21; E-mail: Jorge.Pasqualini@wanadoo.fr.


First Annual Scientific Meeting of the International Society for the Prevention of Tobacco Induced Diseases (PTID Society); Centuries of Tobacco Caused Diseases and Mortality, October 28–30, 2002, Essen, Germany. For more information see the web: www.ptid2002.info or contact per fax: +49 (40) 360.395.9983 or e-mail: TOXICOL98@AOL.COM.

18th World Congress of Digestive Surgery and 9th Hong Kong International Cancer Congress, December 8–11, 2002, Hong Kong Convention and Exhibition Centre, Wanchai, Hong Kong. Contact: Congress Secretariat, 18th World Congress of Digestive Surgery (WCDS2002), Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong. Phone: 852.2818.0232/852.2855.4235; Fax: 852.2818.1186; E-mail: wcds2002@hkucc.hku.hk; Website: http://www.wcds2002.org.
Corrections

In the article by J. A. Loncaster et al., entitled “Carbonic Anhydrase (CA IX) Expression, a Potential New Intrinsic Marker of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix,” which appeared in the September 1, 2001 issue of Cancer Research (pp. 6394–6399), the sixth author’s name appeared incorrectly as Charles C. Wycoff. The author’s correct name is Charles C. Wykoff.

Charles C. Wykoff

In the article by T. L. Frandsen et al., entitled “Direct Evidence of the Importance of Stromal Urokinase Plasminogen Activator (uPA) in the Growth of an Experimental Human Breast Cancer Using a Combined uPA Gene-Disrupted and Immunodeficient Xenograft Model,” which appeared in the January 15, 2001 issue of Cancer Research (pp. 532–537), the equation on page 534 appeared incorrectly as:

\[ \frac{L_v}{H_{11549}} \frac{Q_v}{H_{11554}} \left( \frac{2}{H_{11554}} \right)^2 \left[ \frac{P(tumor)}{H_{20858}} \right] \]

The correct equation appears below.

\[ L_v(vase/tumor) = \frac{Q_v(vase)}{2 \cdot 2 \cdot \Sigma P(tumor)} \]

Thomas Leth Frandsen
Claus Holst-Hansen
Boye Schnack Nielsen
Ib Jarle Christensen
Jens R. Nyengaard
Peter Carmeliet
Nils Brüner

Erratum

In the correspondence from B. Pasche et al., entitled “TβR-I(6A) Association with Colorectal Cancer: A New Twist,” which appeared in the November 15, 2001 issue of Cancer Research (pp. 8351–8352), the second sentence appeared incorrectly as, “Eighteen of these patients were TβR-I(6A) homozygotes.” The correct sentence is, “Eighteen of these patients were TβR-I(6A) heterozygotes.”
Direct Evidence of the Importance of Stromal Urokinase Plasminogen Activator (uPA) in the Growth of an Experimental Human Breast Cancer Using a Combined uPA Gene-Disrupted and Immunodeficient Xenograft Model

Thomas Leth Frandsen, Claus Holst-Hansen, Boye Schnack Nielsen, et al.


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/2/532

Cited articles  This article cites 37 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/2/532.full.html#ref-list-1

Citing articles  This article has been cited by 14 HighWire-hosted articles. Access the articles at:
/content/61/2/532.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.